In a recent study on lebrikizumab maintenance treatment, AD patients who responded by Week 16 saw meaningful long-term results. After up to 3 years of treatment, around 80% of these responders achieved nearly clear skin (measured by EASI 90), with over half of patients experiencing complete skin clearance (EASI 100 or IGA 0). Additionally, one-third of these patients reported quality of life improvements as indicated by POEM scores reflective of minimal to no symptoms of their AD while on continuous therapy with lebrikizumab. Most patients also did not require rescue therapies like additional topical or systemic treatments while using lebrikizumab. These findings highlight that long-term total skin clearance is a realistic goal for at least half of patients who respond to monotherapy lebrikizumab by Week 16.
Click here for a link to the original poster
Elevate-Derm Alliance Editorial Committee